Evaluation of a Patient with Spinal Cord Infarction after a Hypotensive Episode
Stroke 45:e203-e205, Vongveeranonchai, N.,et al, 2014
Headaches, Delusions, and Catharsis
Lancet 374:1652, Etgen,T.,et al, 2009
Clinicopath Conf., Primary Diffuse Large-B-Cell Lymphoma of the Brain
NEJM 352:185-194, Case 1-2005, 2005
Spontaneous Dissection of the Carotid and Vertebral Arteries
NEJM 344:898-906, Schievink,W.I., 2001
Cocaine and Levamisole Cerebral Toxicity
Ann Neurol 89:1253-1254, Allard, J.,et al, 2021
Imaging Findings After Mechanical Thrombectomy in Acute Ischemic Stroke
Stroke 50:1618-1625, Puntonet, J.,et al, 2019
Infliximab for the Treatment of CNS Sarcoidosis
Neurol 89:2092-2100, Gelfand, J.M.,et al, 2017
Clinicopathologic Conference, Neurosarcoidosis
NEJM 374:1966-1975, Case 15-2016, 2016
Clinicopathologic Conference, Oligdendroglioma II/IV with IDH1 R132H mutation and codelation of 1p and 19q
NEJM 375:2381-2389, Case 38-206, 2016
Radiation Necrosis in Pediatric Patients with Brain Tumors Treated with Proton Radiotherapy
AJNR 36:1572-1578, Kralik, S.F.,et al, 2015
Autoimmune Post-Herpes Simplex Encephalitis of Adults and Teenagers
Neurol 85:1736-1743, 1730, Armangue, T.,et al, 2015
Hashimotos Encephalopathy: A Report of Three Cases and Relevant Literature Reviews
Int J Clin Exp Med 8:16817-16826, Zhu, Y.,et al, 2015
Radiosurgery for Metastatic Spinal Tumors: Follow-Up MR Findings
AJNR 33:382-387, Hwang,Y.J.,et al, 2012
Clinicopathologic Conference, Glioblastonoma, WHO grade IV of IV, with Methylation of the MGMT Promoter
NEJM 366:2112-2120, Case 17-2012, 2012
Vemurafenib for Melanoma Metastases to the Brain
NEJM 365:2439-2441, Rochet, N.M.,et al, 2011
Impact od Adjuvant Chemotherapy for Gliomatosis Cerebri
BMC Cancer 10:424, Kong, D-S.,et al, 2010
Natalizumab Plus Interferon Beta -1a for Relapsing Multiple Sclerosis
NEJM 354:911-923,965, Rudick,R.A.,et al, 2006
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
NEJM 354:899-910,965, Polman,C.H.,et al, 2006
Pre- and Posttreatment MR Imaging Findings in Lead Encephalopathy
AJNR 27:902-903, Atre,A.L.,et al, 2006
Magnetic Resonance Imaging as a Surrogate Outcome Measure of Disability in Multiple Sclerosis: Have We Been Overly Harsh in Our Assessment?
Ann Neurol 59:597-605, Goodin,D.S., 2006
Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis
NEJM 355:1124-1140, Kappos,L.,et al, 2006
Management of Acute Cerebellar Stroke
Arch Neurol 62:537-544, Jensen,M.B. &St. Louis,E.K., 2005
Primary Angiitis of the Central Nervous System: Emerging Variants
Q J Med 98:643-654, Maclaren,K.,et al, 2005
Angiography-Negative Primary Central Nervous System Vasculitis in Children
Arthritis Rheum 52:2159-2167, Benseler, S.M.,et al, 2005
Intravenous Immunoglobulin Treatment Following the First Demyelinating Event Suggestive of Multiple Sclerosis
Archn Neurol 61:1515-1520, Achiron,A.,et al, 2004
Clinically Mild Encephalitis Encephalopathy with a Reversible Splenial Lesion
Neurol 63:1854-1858, Tada,H.,et al, 2004
A Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
NEJM 348:14-23, Miller,D.H.,et al, 2003
Benefit of Interferon B-1a on MSFC Progression in Secondary Progressive MS
Neurol 59:679-687, Cohen,J.A.,et al, 2002
Late Secondary Ischemic Injury in Patients Receiving Intraarterial Thrombolysis
Ann Neurol 52:698-703,695, Kidwell,C.S.,et al, 2002
Copaxone's Effect on MRI-Monitored Disease in Relapsing MS is Reproducible and Sustained
Neurol 59:1284-1286, Wolinsky,J.S.,et al, 2002
Hemichorea-Hemiballism in Primary Diabetic Patients: MR Correlation
J Comput Assist Tomogr 26:905-911, Lee,E.J.,et al, 2002
European/Canadian Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Effects of Glatiramer Acetate on Magnetic Resonance Imaging-Measured Disease Activity and Burden in Patients wi
Ann Neurol 49:290-297, Comi,G.,et al, 2001
Randomized Controlled Trial of Interferon-beta-1a in Secondary Progressive MS
Neurol 56:1505-1513, Li,D.K.B.,et al, 2001
The Effect of IFNB-1b on the Evolution of Enhancing Lesions in Secondary Progressive MS
Neurol 57:2185-2190, Brex,P.A.,et al, 2001
Tectal Gliomas: Natural History of an Indolent Lesion in Pediatric Patients
Pediatr Neurosurg 32:24-29, Bowers,D.C.,et al, 2000
Interferon-alpha 2a Reduces MRI Disease Activity in Relapsing-Remitting Multiple Sclerosis
Neurol 52:1049-1056, Myhr,K.M.,et al, 1999
MR of CNS Sarcoidosis:Correlation of Imaging Features to Clinical Symptoms and Response to Treatment
AJNR 20:655-669, Christoforidis,G.A.,et al, 1999
MR Imaging Response of Brain Metastases after Gamma Knife Stereotactic Radiosurgery
Radiology 211:807-814, Peterson,A.M.,et al, 1999
Magnetic Resonance Imaging Results of the PRISMS Trial:A Randomized, Double-Blind, Placebo-Controlled Study of Interferon-B1a in Relapsing-Remitting Multiple Scleroosis
Ann Neurol 46:197-206, Li,D.K.B.,et al, 1999
Evidence of Interferon B-1a Dose Response In Relapsing-Remitting MS, The OWIMS Study
Neurol 53:679-686, The Once Weekly Interferon for MS Study Group (OWI, 1999
Interferon-B-1a in Relapsing-Remitting Multiple Sclerosis:Effect on Hypointense Lesion Volume on T1 Weighted Images
JNNP 67:579-584, Gasperini,C.,et al, 1999
Spinal Epidural Lipomatosis in a Patient with the Ectopic Corticotropin Syndrome
NEJM 341:1399-1400, Koch,C.A.,et al, 1999
Susac Syndrome
Medicine 77:3-11, Papo,T.,et al, 1998
Effect of Steroids on Gd-Enhancing Lesions Before & During Beta Interferon 1a Trtm in Relapsing Remitting MS
Neurol 50:403-406, Gasperini,C.,et al, 1998
Regress of HIV Enceph & Basal Ganglia Signal Intensity Abnor MRI in AIDS after Protease Inhibitor
Neuroradiology 206:491-498, Filippi,C.G.,et al, 1998
Effects of Copolymer-1 on Serial Gadolinium-Enhanced MRI in Relapsing Remitting Multiple Sclerosis
Neurol 50:1127-1133, Mancardi,G.L.,et al, 1998
Intravenous Immunoglobulin G Reduces MRI Activity in Relapsing Multiple Sclerosis
Neurol 50:1273-1281, Sorensen,P.S.,et al, 1998
Randomized Trial Comparing Two Different High Doses of Methylprednisolone in MS, A Clinical and MRI Study
Neurol 50:1833-1836, Oliveri,R.L.,et al, 1998
Randomised Double-Blind Placebo-Controlled Study of Interferon B-1a in Relapsing/Remitting Multiple Sclerosis
Lancet 352:1498-1504,1486, PRISMS, 1998